Mecoxcuremed Launches Phase 2 Clinical Trial of Natural Arthritis Treatment 'Bozanics'

[Asia Economy Reporter Jang Hyowon] MedicoX, a KOSDAQ-listed company, announced on the 25th that its subsidiary specializing in new drug development, Mecox CureMed, has commenced the Phase 2 clinical trial of its self-developed arthritis treatment drug, 'Bozanics.'

Bozanics is a natural product-based arthritis treatment developed by Mecox CureMed. It is known for its excellent pain relief and anti-inflammatory effects on arthritis, with minimal side effects, making the drug highly safe. Mecox CureMed previously received simultaneous approval for the Phase 1 and Phase 2 clinical trial plans for Bozanics.

The Phase 2 clinical trial of Bozanics will be conducted as a comparative study against 'Celecoxib' 200 milligrams, currently the most prescribed drug for patients with knee and hip osteoarthritis. The company explained that the trial will comprehensively evaluate the drug’s effects on pain relief caused by inflammation, structural changes in lesions, treatment satisfaction, changes in objective indicators such as inflammation markers, and overall safety. The company aims to complete Phase 2 and quickly proceed to Phase 3.

The Phase 2 clinical trial of Bozanics will be a multi-center joint study involving more than 180 patients across six institutions: Bundang Seoul National University Hospital, Seoul Boramae Hospital, Ajou University Hospital, Chonnam National University Hospital, Chosun University Hospital, and Busan Paik Hospital.

Mecox CureMed completed the Phase 1 clinical trial of Bozanics in October last year in collaboration with Bundang Seoul National University Hospital. The Phase 1 trial involved a total of 36 clinical trial subjects who received single and multiple doses across six dosage groups. The trial confirmed tolerability and safety without any adverse reactions in all subjects, achieving significant results.